57 results
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
7 Feb 24
23andMe Reports Third Quarter Fiscal 2024 Financial Results
4:03pm
)
Three Months Ended December 31,
Nine Months Ended December 31,
Revenue
Cost of revenue
Gross profit
Operating expenses:
Research and development
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
% Note: Fiscal year ends March 31.
37Copyright © 2024 23andMe, Inc. Research and Development Expense Composition Three Months Ended September 30, YoY
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Nov 23
23andMe Reports Second Quarter Fiscal 2024 Financial Results
4:29pm
of revenue
Gross profit
Operating expenses:
Research and development
Sales and marketing
General and administrative
Restructuring and other charges
Total
8-K
f7aezw
30 Oct 23
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
4:05pm
8-K
EX-99.1
7ygopcidt
8 Aug 23
23andMe Reports FY2024 First Quarter Financial Results
4:10pm
DEFR14A
fg6djih6ri mk1ipcwk
26 Jul 23
Revised proxy
9:14pm
8-K
EX-99.1
r5v81rq497r
25 May 23
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
4:08pm
8-K
EX-99.1
xap9wert
17 Apr 23
Regulation FD Disclosure
4:10pm
8-K
EX-99.1
9fn4npm hh5f4c
9 Nov 22
Investor Presentation November 2022
7:30am
424B3
ly1 7io8rch6l05zjk
7 Nov 22
Prospectus supplement
4:33pm
8-K
EX-99.1
2i2jrzvuq4h xf9h
7 Nov 22
23andMe Reports FY2023 Second Quarter Financial Results
4:06pm
8-K
EX-99.1
qcoscz4e35cek649y94s
18 Aug 22
Investor Presentation August 2022
4:06pm
424B3
92relq
16 Aug 22
Prospectus supplement
6:12pm